Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed

Theravance Biopharma, Inc.

2024-Q2 EPS reported -$0.58 revenue$28,759,000

Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.
Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).
YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.
CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.
TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.